Search

The University of Kansas Medical Center conducted a study on the successful use of a midline catheter for leukapheresis in patients undergoing collection for immune effector cell therapy. The research showed that apheresis through a midline catheter was feasible and effective in most populations, potentially reducing the need for central venous catheter access. This study, published in the Journal of Clinical Apheresis, highlights the importance of utilizing limited healthcare resources efficiently in cellular therapy procedures. [Extracted from the article]

The article discusses an Expanded Access Program (EAP) for Obecabtagene Autoleucel (obe-cel) for adult patients with Acute Lymphoblastic Leukemia (ALL) whose treatment product is deemed out-of-specification (OOS). The program aims to provide access to obe-cel for patients with limited treatment options and describes the safety profile of obe-cel within the first 45 days after infusion. The study is a single-arm, open-label, multicenter EAP for adult patients diagnosed with recurring or refractory ALL. Patients must meet specific eligibility criteria to participate in the study, and data will be collected from routine medical records for analysis. [Extracted from the article]

A clinical trial, NCT06768905, is being conducted to assess the safety, efficacy, and tolerability of a single 50 mCi dose of 131I-Apamistamab followed by axicabtagene ciloleucel infusion in patients with Relapsed or refractory (R/R) Diffuse large B-cell lymphoma (DLBCL). The study involves a 6-patient safety run-in to evaluate safety measures. The trial aims to determine the impact of this treatment regimen on patients with DLBCL, with a primary completion date set for May 31, 2028. [Extracted from the article]

The article discusses a clinical trial, NCT06759181, evaluating the efficacy and safety of Anti-BCMA/FcRL5 CAR-T cells in patients with relapsed and refractory multiple myeloma. The study involves a leukapheresis procedure to manufacture the modified T cells, followed by lymphodepleting therapy with fludarabine and cyclophosphamide before infusion. The trial aims to assess outcomes such as adverse events, overall response rate, complete response, overall survival, and event-free survival over a period of 24 months. The study is recruiting participants in China and is expected to be completed by December 31, 2027. [Extracted from the article]

The article discusses a Phase I/II clinical trial, NCT06762431, evaluating the safety and efficacy of concomitant therapy with anti-CD19 CAR T-cells and Lenalidomide in adult patients with relapsed/refractory chronic lymphocytic leukemia (CLL). The trial involves pretreating patients with Ibrutinib for 3 months prior to leukapheresis, followed by lymphodepleting chemotherapy and infusion of CAR T-cells at fixed dose levels, along with Lenalidomide intake. The study aims to explore safety, tolerability, pharmacokinetics of CAR-T cells, overall response rate, duration of response, progression-free survival rates, overall survival rates, and MRD negativity rates. The trial is currently enrolling participants in Belarus. [Extracted from the article]

A recent study conducted by Massachusetts General Hospital and Harvard Medical School introduced a new method for analyzing circulating tumor cells (CTCs) in blood samples, which can provide valuable insights into cancer progression. By utilizing a high-throughput microfluidic device, researchers were able to enrich CTCs from large blood volumes, revealing significant intra-patient heterogeneity and subclonal patterns of aneuploidy and distinct signaling pathways within CTCs. This innovative approach enables comprehensive monitoring of cancer through cell-based liquid biopsy, offering potential benefits for cancer diagnosis and treatment. [Extracted from the article]

Researchers from Amrita Vishwa Vidyapeetham in India conducted a study to determine the feasibility of establishing a CAR-T cell therapy center in a resource-limited setting to treat relapsed or refractory B-cell malignancies. The study involved treating 8 patients with a median age of 38 years, with most patients needing to raise funds for their treatment through crowdfunding. Despite challenges such as high costs and resource constraints, the therapy was effectively implemented, showing potential for similar environments. The study concluded that while there were limitations in the data, the results highlight the therapy's promise in resource-constrained settings. [Extracted from the article]

A recent study conducted at Washington University School of Medicine focused on reducing relapse rates in pediatric and young adult patients with high-risk AML after haploidentical transplant. The study involves the adoptive transfer of novel NK cell products following TCRab T cell depleted haplo-HCT, aiming to enhance graft versus leukemia effects without causing graft-versus-host disease. The primary objective of the study is to assess the safety and feasibility of this approach, with secondary objectives including estimating relapse-free survival and defining donor NK cell expansion and interactions with other immune populations. The study is expected to be completed by April 2027 and is registered at clinicaltrials.gov. [Extracted from the article]

A recent study conducted at the University of Minnesota Medical Center focused on developing a new treatment for hemophilia B called BE-101. This treatment involves genetically engineering B lymphocyte lineage cells to express and secrete Factor IX, aiming to restore clinically meaningful levels of the protein in adults with moderately severe or severe hemophilia B. The study, known as BeCoMe-9, is a Phase 1/2 clinical trial that aims to evaluate the safety and efficacy of BE-101 through a dose-escalation and expansion approach. Researchers hope that this new treatment could offer durable and tunable therapeutic effects for individuals with hemophilia B. [Extracted from the article]

A study conducted at Mayo Clinic examined the correlation between pre-apheresis biomarkers and the development of severe cytopenias and therapy-related myeloid neoplasms in non-Hodgkin lymphoma patients undergoing chimeric antigen receptor T-cell therapy. The research identified factors such as age, platelet count, ferritin levels, and LDH as associated with prolonged cytopenia, while advanced age, anemia, high ferritin levels, and a history of three lines of therapy were linked to the development of therapy-related myeloid neoplasms. These findings could potentially aid in patient counseling and therapy selection by identifying those at high risk of hematotoxicity and myeloid neoplasm development. [Extracted from the article]

A recent study conducted at Vanderbilt University Medical Center examined the impact of patient distance from the center on outcomes and costs for individuals undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma. The study found that longer distances from CAR-T centers may be associated with inferior infection and survival outcomes. Patients who lived more than 90 miles from the center experienced higher non-relapsed mortality and infection-related deaths. The research suggests the need for future multicenter studies to address barriers to access and supportive care for patients undergoing CAR-T therapy. [Extracted from the article]

The research from the Weizmann Institute of Science in Israel focuses on using single-cell analysis to predict outcomes of CAR-T cell therapy in patients with Diffuse Large B-Cell Lymphoma. By analyzing peripheral blood samples, researchers identified specific cellular and molecular features associated with treatment response. The study found that patients with high B-cells in their blood at the time of leukapheresis achieved complete remission, while non-responders showed enrichment of specific myeloid cell populations. The findings suggest potential biomarkers for predicting treatment response and improving personalized therapy for high-risk patients. [Extracted from the article]

Cryoport, Inc. has opened a new IntegriCell facility in Villers-le-Bouillet, Liege, Belgium, to support the development and commercialization of cell-based therapies. This standardized bioprocessing and cryopreservation solution aims to enhance manufacturing efficiency and product stability for cell therapies. The facility has the capacity to cryopreserve over 1,100 leukapheresis products annually, providing high-quality cryopreserved leukopaks for cell-based therapy programs. CEO Jerrell Shelton highlights the facility's role in delivering consistent cryopreservation solutions to the cell therapy community and supporting the efficient delivery of transformative therapies to patients. [Extracted from the article]

The article discusses a phase II clinical trial comparing the effects of folate receptor alpha dendritic cells (FRaDCs) to a placebo in treating patients with advanced stage ovarian cancer. FRaDCs are a type of dendritic cell vaccine made from a person's white blood cells and target a protein found in high levels on ovarian tumor cells. The trial aims to evaluate the efficacy of FRaDCs in preventing or delaying recurrence in patients with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer. The study is set to be completed by December 31, 2027, and focuses on outcomes such as recurrence-free survival and overall survival in patients receiving FRaDCs compared to a placebo. [Extracted from the article]

The Memorial Sloan Kettering Cancer Center is conducting a Phase I clinical trial, NCT06623396, to investigate the safety and effectiveness of intraperitoneal mesothelin-targeted CAR T-cell therapy in patients with mesothelin-positive esophagogastric adenocarcinoma with peritoneal carcinomatosis. The trial aims to enroll 18 participants who will have their white blood cells collected and modified in the laboratory to become MSLN-targeted CAR T cells. The therapy will be administered over a 3-4 week period. The document provides detailed criteria for inclusion and exclusion in the trial, including timeframes for obtaining tissue samples and medical conditions that would prevent enrollment. The study is open to individuals of all genders aged 18 years and older. Administrative information, such as the study ID number and data sharing plan, is also included. [Extracted from the article]

A study conducted at Oslo University Hospital in Norway examined the management of hyperleukocytosis in pediatric acute myeloid leukemia (AML). The researchers recommended immediate initiation of full-dose chemotherapy using etoposide monotherapy without leukapheresis or prephase chemotherapy. The study found that this approach was feasible, safe, and effective, with a reduction in white blood cell count comparable to leukapheresis. The five-year event-free and overall survival rates for patients with hyperleukocytosis were slightly lower than those without hyperleukocytosis. The researchers concluded that early initiation of induction chemotherapy is crucial for managing hyperleukocytosis in pediatric AML. [Extracted from the article]

Researchers from Universite Paris Cite have published a study on the use of neurofilament light chain (NfL) levels as a predictive biomarker for neurotoxicity after CAR T-cell therapy. The study found that elevated NfL levels at the time of CAR T-cell infusion were associated with the severity of immune effector cell-associated neurotoxicity syndrome (ICANS). The researchers concluded that incorporating NfL levels into the decision-making process could help guide the management of ICANS and determine the appropriate CAR product for each patient. This research provides valuable insights for the development of personalized treatments for patients undergoing CAR T-cell therapy. [Extracted from the article]

A clinical trial has been launched to investigate the potential cure of HIV infection in patients who have undergone a stem cell transplant. The trial involves closely monitoring patients whose blood shows no detectable levels of the HIV virus after leukapheresis, a process of collecting blood. These patients will discontinue their antiretroviral therapy (ART) and be regularly tested and monitored for up to 52 weeks. If they remain HIV-free during this period, they may be considered cured of their HIV infection. The trial is currently in the recruitment phase and aims to enroll 10 participants. [Extracted from the article]

This document provides information about a clinical trial in China, NCT06567366, which is investigating the use of a drug called Glofitamab in combination with CAR T-cell therapy for the treatment of large B-cell lymphoma. The trial aims to evaluate the efficacy and safety of this treatment option and will assess various outcome measures such as response rates, duration of response, and survival rates. The trial is currently in the interventional phase and is designed as a single-group trial with the primary purpose of treatment. Eligible participants must have relapsed or refractory lymphoma and meet certain prognostic factors. The trial is not yet recruiting participants, and it is projected to be completed in September 2027. [Extracted from the article]

The article focuses on a clinical trial assessing the safety, side effects, and optimal dosage of the drug NEXI-001 combined with decitabine and lymphodepleting chemotherapy for treating relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) following allogeneic hematopoietic cell transplantation. It explains that the study aims to determine the recommended dose and evaluate the treatment's anti-leukemic activity, including response rates and survival outcomes.

The article focuses on a Phase 2, open-label, randomized clinical trial evaluating the combination of pirtobrutinib and brexucabtagene autoleucel in patients with relapsed or refractory mantle cell lymphoma. Topics include the study design and goals, which involve assessing progression-free survival and comparing the efficacy and safety of concurrent pirtobrutinib versus no concurrent pirtobrutinib, as well as the secondary outcomes related to severe adverse events and overall response rates.

A recent study conducted at Zhongnan Hospital of Wuhan University explored the use of leukapheresis, a procedure that reduces white blood cell count, in patients with hyperleukocytic acute myeloid leukemia. The study found that leukapheresis treatment resulted in a significant decrease in white blood cells and a decrease in infection rates compared to non-apheresis treatment. However, the study also noted that leukapheresis treatment can be damaging to cells and that the optimal centrifugation parameters need to be determined to minimize cell damage. The research concluded that the cells obtained under the optimal centrifugation parameters can be successfully cryopreserved and used to establish leukemia animal models, which can improve the efficiency and reduce the side effects of leukapheresis. [Extracted from the article]

A recent study conducted at the University of Houston explores the potential of microfluidic cell separation methods to enable centrifugation-free, low extracorporeal volume (ECV) leukapheresis in pediatric patients. Leukapheresis is a procedure used to remove white blood cells from a patient's blood. The study highlights the challenges and advancements in passive separation methods and discusses their potential for future use as a high-throughput microfluidic leukapheresis platform. The research was supported by the NIH National Heart Lung & Blood Institute (NHLBI) and has been peer-reviewed. [Extracted from the article]

This document provides information about a clinical trial in China for the treatment of relapsed or refractory large B-cell lymphoma (LBCL). The trial is studying the use of a biological treatment called Relma-cel, which involves the administration of CAR+T cells. The study aims to evaluate the effectiveness, safety, and pharmacokinetics of Relma-cel in LBCL patients. The trial is currently in the interventional phase and is expected to be completed by April 2025. [Extracted from the article]

This document provides information about an ongoing clinical trial conducted by Tianjin Medical University Cancer Institute and Hospital in China. The trial, with the NCT number NCT06484790, aims to evaluate the safety and effectiveness of autologous TCR-T cell therapy in individuals with advanced solid tumors. Specifically, the trial focuses on the use of autologous anti-KRAS G12V/G12D mutation T-cell Receptor T cell in advanced solid tumors. The study is currently in the recruiting phase and is expected to be completed by April 2026. The trial is open to both male and female participants aged 18 to 75 and focuses on pancreatic cancer, colorectal cancer, and lung adenocarcinoma cancer. Contact information for the primary and backup contacts for the trial is also provided. [Extracted from the article]

A recent study conducted at the Mayo Clinic in Rochester, Minnesota, examined the factors that contribute to severe cytopenia and therapy-related myeloid neoplasms (t-MN) in patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy for hematological malignancies. The study found that advanced age, anemia, and thrombocytopenia at the time of evaluation for CAR-T eligibility were associated with the development of post-treatment severe cytopenia and t-MN. The researchers recommend further multi-center studies to validate these findings. This information is valuable for patients and healthcare providers in making informed decisions about CAR-T therapy and stem cell collection. [Extracted from the article]

AstraZeneca has conducted research on the cryopreservation and banking of patients' leukapheresis materials for CAR-T cell therapies. The study aimed to determine the optimal temperature range for transferring cryopreserved materials from controlled rate freezers to ultracold storage without affecting CAR-T cell production and functionality. The findings showed that there is no significant influence on CAR-T cell expansion, differentiation, or in-vitro function when transferring materials at temperatures ranging from -30 degrees C to -80 degrees C. This research suggests that cryopreserved materials can be safely transferred at higher temperatures for autologous CAR-T cell therapies. [Extracted from the article]

The patent application titled "Expedited Administration of Engineered Lymphocytes" outlines a method for manufacturing and administering engineered lymphocytes to treat cancer. The process involves obtaining lymphocytes from a patient, modifying them with a polynucleotide vector, culturing the modified lymphocytes, and reintroducing them into the patient within 28 days. This method aims to reduce the risk of thrombocytopenia and has shown promising response rates. Additionally, the application discusses methods for predicting treatment outcomes and the likelihood of thrombocytopenia in patients receiving immunotherapy. The patent application specifically focuses on preventing and reducing thrombocytopenia in patients with relapsed/refractory large B-cell lymphoma. [Extracted from the article]

A recent study conducted by researchers at the Institute Curie highlights the effectiveness of CAR T-cell therapy in treating relapsed primary central nervous system lymphoma (PCNSL). The study, which included the largest cohort of PCNSL patients treated with CAR T-cells worldwide, found that the therapy induced a high rate of prolonged remission and had a reassuring tolerance profile. The results of the study were significantly better than those typically observed in this setting. This research provides valuable insights into the potential of CAR T-cell therapy for the treatment of PCNSL. [Extracted from the article]

A clinical trial, NCT06350110, is being conducted in China by Essen Biotech to investigate the use of BH002 injection (CD19-BCMA CAR-T cells) in treating patients with resistant systemic lupus erythematosus (SLE). The trial aims to determine the highest dose of the injection that patients can tolerate. SLE is an autoimmune disorder characterized by the production of autoantibodies, and conventional treatment aims to achieve remission. CD19-BCMA CAR-T cells offer a potential solution by targeting and eliminating abnormal B cells responsible for antibody production. The trial will evaluate the safety and effectiveness of this new treatment approach using CD19/BCMA-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy for patients with specific hematologic malignancies. The treatment regimen involves the administration of fludarabine phosphate and cyclophosphamide before the infusion of CD19/BCMA-CAR T cells. Eligible patients may receive additional doses if they respond well to the initial infusion. The trial is not yet recruiting and is estimated to be completed by December 2025. [Extracted from the article]

A study conducted by researchers at Washington University in St. Louis investigated the impact of bridging therapy (BT) on the outcome of patients with relapsed/refractory large B-cell lymphoma who received antilymphoma treatment between leukapheresis and axicabtagene ciloleucel (axi-cel) infusion. The study analyzed data from the multicenter US Lymphoma CAR-T Consortium and found that patients who received BT had similar outcomes to those who did not receive BT in terms of overall response rate, complete response rate, progression-free survival, and overall survival. The study also found that radiation-based BT did not provide clear advantages over nonradiation-based BT. These findings suggest that BT may be safe without significantly impacting long-term survival for patients who require disease stabilization during the manufacturing period. [Extracted from the article]

A recent preprint abstract discusses the potential of tumor cell-based liquid biopsy for cancer patients. The abstract highlights the challenges of isolating circulating tumor cells (CTCs) due to their rarity and the limitations of current technologies. The researchers describe a high-throughput microfluidic prototype that can process large blood volumes and isolate a sufficient number of CTCs for analysis. This technology allows for the characterization of CTCs' morphological and molecular heterogeneity, including gene copy number variation, which has potential diagnostic applications. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

A recent study conducted at Toyohashi Municipal Hospital in Japan has found that measuring hematopoietic progenitor cells (AP-HPCs) in leukapheresis products using Sysmex XN-series analyzers can help determine if a sufficient number of CD34+ stem cells have been collected. This is particularly important when using plerixafor, a stem cell-mobilizing drug that requires administration the day before leukapheresis. The study found a strong correlation between AP-CD34+ and AP-HPC counts, with AP-HPCs being able to identify cases where enough stem cells have been collected. This research has been peer-reviewed and published in Internal Medicine. [Extracted from the article]

A recent study conducted in Milan, Italy, has found that CD19-targeted CAR T-cell therapy can induce durable remissions in relapsed/refractory large B-cell lymphomas (R/R LBCL), but 60% of patients do not respond or relapse. The researchers performed transcriptomic and functional evaluations of leukapheresis products in 95 R/R LBCL patients and identified a signature composed of 4 myeloid genes expressed by T cells isolated from leukapheresis products that can predict patients with a very short progression-free survival. The study also found that high circulating absolute monocyte counts at the time of leukapheresis negatively influenced response and progression-free survival. This research highlights the need to incorporate monocyte depletion strategies for better CAR T production and could be used to plan trials evaluating CAR T cells versus other novel treatments or allogeneic CAR T cells. [Extracted from the article]

This document provides information about a pilot study that aims to evaluate the feasibility and safety of using cytomegalovirus-specific, anti-HIV chimeric antigen receptor (CMV-HIV CAR) T cells as a potential immunotherapy for people living with HIV. The study focuses on the use of CAR T cells engineered to target HIV-infected cells, with the goal of eliminating these cells. The researchers propose using autologous CMV-specific T cells, which can be stimulated by endogenous CMV, to address the issue of low persistence of CAR T cells. The study is in its early stages and aims to assess the presence and effectiveness of CMV/HIV-CAR T cells in healthy individuals living with HIV. [Extracted from the article]

Researchers at the University of Twente in Enschede, Netherlands have developed a new method for capturing circulating tumor cells (CTCs) from diagnostic leukapheresis (DLA) samples. The method, called flow enrichment target capture Halbach-array (FETCH), reduces cell clumping and allows for the processing of larger fractions of DLA samples. The researchers found that using FETCH resulted in a significant increase in the number of CTCs detected compared to the current CellSearch method. This research has the potential to improve the clinical utility of CTCs in the diagnosis and treatment of cancer. [Extracted from the article]

This document provides information on a Phase I/II clinical study being conducted in China to evaluate the effectiveness and safety of a chimeric antigen receptor T-cell therapy called GC012F in patients with relapsed/refractory multiple myeloma. The study is open to both male and female participants aged 18-75 who have received at least three prior lines of therapy and meet specific laboratory and organ function requirements. Eligible subjects will receive a single dose of GC012F infusion after lymphodepletion. The study is currently recruiting and is expected to be completed by June 2026. [Extracted from the article]

A recent study conducted at University Hospital Heidelberg in Germany has found that symptomatic patients with hyperleukocytic FLT3-ITD mutated acute myeloid leukemia (AML) may benefit from leukapheresis. The study aimed to identify subsets of patients who would benefit from emergency leukapheresis and establish a therapeutic algorithm for AML patients with hyperleukocytosis. The research found that FLT3-ITD mut AML patients who received leukapheresis had a significantly higher median overall survival (OS) of 437 days compared to FLT3 wt AML patients, who had a median OS of only 5 days. These findings suggest that leukapheresis may improve outcomes for certain AML patients with hyperleukocytosis. [Extracted from the article]

A clinical trial, NCT06172296, is being conducted to test the effectiveness of adding dinutuximab to standard treatment for children with high-risk neuroblastoma. The trial will evaluate the combination of dinutuximab with chemotherapy, surgery, radiation, and stem cell transplantation. It aims to assess survival rates, response rates, adverse events, and other outcome measures. The trial is set to start in 2024 and is expected to be completed by 2029. This phase III trial aims to determine the effectiveness of adding dinutuximab to induction chemotherapy for the treatment of children with high-risk neuroblastoma. The trial will assess survival rates, response rates, toxicities, and explore biomarkers and markers of minimal residual disease. Various treatments and procedures, including radiation, dinutuximab, and scans, are involved in the study. The study is in Phase 3 and is designed as a randomized intervention. The primary purpose is treatment, and patients are followed up after completing the study treatment. The document provides a list of medications, procedures, and alternative names related to cancer treatment. It also provides a list of drugs, procedures, and alternative names for a clinical trial. The trial, known as ANBL2131, is being conducted by the National Cancer Institute (NCI) and aims to study the treatment of high-risk neuroblastoma in patients up to 30 years old. The trial is investigating various aspects of the disease, including genetics [Extracted from the article]

A patent application titled "Methods Of Inducing Stem Cell Mobilization" has been published by the US Patent and Trademark Office. The application, filed by inventors from South Korea, describes a method for mobilizing stem cells from the bone marrow into the blood. This method involves using an IL-7 protein, either alone or in combination with other agents, to increase the number of stem cells in the blood. The invention aims to improve stem cell transplantation and the recovery of the blood system in patients undergoing chemotherapy or radiation therapy. The assignee for this patent application is NeoImmuneTech Inc. [Extracted from the article]

A recent study conducted by researchers from the University of Western Ontario in Canada focused on mantle cell lymphoma (MCL), an aggressive B-cell non-Hodgkin lymphoma. The study examined the occurrence of leukostasis, a condition characterized by high white blood cell counts, in MCL patients. The researchers conducted a systematic review of existing literature and presented a case study of a patient with MCL who experienced leukostasis. The study found that leukapheresis, a procedure to reduce white blood cell counts, was effective in treating leukostasis in MCL patients. However, in hospitals without leukapheresis capabilities, high doses of IV methylprednisolone were found to be a safe and effective alternative. The study highlights the importance of recognizing leukostasis symptoms in MCL patients and offers potential treatment strategies. [Extracted from the article]

A study conducted at Chang Gung Memorial Hospital has found that manufacturing a subsequent autologous CAR-T product after prior CAR-T therapy is safe and feasible for patients with large B-cell lymphoma. The study evaluated the impact of residual CAR19 on CAR22 production and patient outcomes. The researchers concluded that serial manufacturing of autologous CAR-T products is safe and feasible, as the levels of CAR19 transcripts were rare and did not contribute to toxicity or clinical outcomes. This research provides valuable insights for the treatment of patients who fail to achieve durable remission following CD19-directed CAR-T therapy. [Extracted from the article]

A recent study conducted by Vanderbilt University Medical Center examined the impact of the time from referral to treatment on outcomes and cost for patients undergoing chimeric antigen receptor (CAR) T-cell therapy for B-cell lymphoma. The study found that the time from referral to CAR-T infusion was longer than expected but did not affect survival outcomes. However, the cost of therapies prior to CAR-T was high, highlighting the need to minimize logistical barriers to reduce costs and improve patient quality of life. The researchers recommend further multicenter studies to better understand the impact of time from referral to treatment on costs, outcomes, and quality of life. [Extracted from the article]

A recent study conducted at Tel Aviv University in Israel has found that point-of-care anti-CD19 CAR T-cell therapy has shown high response rates in adults with relapsed/refractory acute B lymphoblastic leukemia (R/R B-ALL). The study involved a phase 1b/2 clinical trial with 28 patients, and the results showed an overall response rate of 88% at one month. The therapy was well-tolerated, with manageable side effects. The researchers concluded that point-of-care CAR T-cell therapy can be an effective treatment option for adults with R/R B-ALL, offering high response and survival rates comparable to FDA-approved CAR T-cell therapies. [Extracted from the article]

A recent report from Vanderbilt University Medical Center discusses the use and impact of post-referral and bridging therapy on outcomes in patients undergoing CAR T-cell therapy for B-cell lymphoma. The study analyzed data from 60 patients who received commercial CAR-T cell therapy at the medical center. The researchers found that the use of post-referral therapy did not affect the 30-day complete remission rate, but patients who received platinum-based chemotherapy as their first post-referral therapy had higher odds of achieving complete remission. Further research is needed to explore this trend and determine optimal treatment choices. [Extracted from the article]

According to a report by Verified Market Research, the global leukapheresis market is projected to grow at a compound annual growth rate (CAGR) of 6.08% from 2021 to 2028. The market was valued at USD 62,767.54 million in 2020 and is expected to reach USD 100,647.54 million by the end of the forecast period. Leukapheresis is a procedure used in hematology to remove white blood cells from the blood. This information is based on a fact-based report that provides research and discoveries from around the world. [Extracted from the article]